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Abstract 
Rationale: Aspects of schizophrenia, including deficits in sensorimotor 
gating, have been linked to glutamate dysfunction and/or oxidative stress in 
the prefrontal cortex. System xc−, a cystine- glutamate antiporter, is a poorly 
understood mechanism that contributes to both cellular antioxidant capacity 
and glutamate homeostasis. 
Objectives: Our goal was to determine whether increased system xc− activity 
within the prefrontal cortex would normalize a rodent measure of 
sensorimotor gating. 
Methods: In situ hybridization was used to map mRNA expression of xCT, the 
active subunit of system xc−, in the prefrontal cortex. Prepulse inhibition was 
used to measure sensorimotor gating; deficits in prepulse inhibition were 
produced using phencyclidine (0.3–3 mg/kg, sc). N-acetylcysteine (10–100 
μM) and the system xc− inhibitor (S)-4-carboxyphenylglycine (CPG, 0.5 μM) 
were used to increase and decrease system xc− activity, respectively. The 
uptake of 14C-cystine into tissue punches obtained from the prefrontal cortex 
was used to assay system xc− activity. 
Results: The expression of xCT mRNA in the prefrontal cortex was most 
prominent in a lateral band spanning primarily the prelimbic cortex. Although 
phencyclidine did not alter the uptake of 14C-cystine in prefrontal cortical 
tissue punches, intra-prefrontal cortical infusion of N-acetylcysteine (10–100 
μM) significantly reduced phencyclidine- (1.5 mg/kg, sc) induced deficits in 
prepulse inhibition. N-acetylcysteine was without effect when co-infused with 
CPG (0.5 μM), indicating an involvement of system xc−. 
Conclusions: These results indicate that phencyclidine disrupts sensorimotor 
gating through system xc− independent mechanisms, but that increasing 
cystine-glutamate exchange in the prefrontal cortex is sufficient to reduce 
behavioral deficits produced by phencyclidine. 
Keywords: schizophrenia, prefrontal cortex, prepulse inhibition, 
phencyclidine, sensorimotor gating, glutamate, system xc−, nonvesicular, 
cystine-glutamate antiporter 
Introduction 
Abnormal activity within the prefrontal cortex has been linked to 
schizophrenia and may contribute to aspects of the disease that are 
only marginally responsive to existing antipsychotic medications 
(Berman et al. 1986; Garey et al. 1998; Glantz and Lewis 2000; 
Lieberman et al. 2005; Rajkowska et al. 1998). Dysregulation of 
excitatory signaling has been widely linked to deficits in prefrontal 
cortical activity observed in schizophrenia (Bunney and Bunney 2000; 
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Javitt et al. 2011; Moghaddam and Javitt 2012), although the nature 
of the potential pathological changes are not clear. Reduced, 
increased, or de-synchronized excitatory activity in the prefrontal 
cortex has been proposed to occur in schizophrenia (Franzen and 
Ingvar 1975; Ingvar and Franzen 1974; Jackson et al. 2004; 
Moghaddam and Adams 1998; Potkin et al. 2009). Identifying the 
cellular basis of prefrontal deficits in more detail, especially as it 
relates to excitatory signaling, will advance our understanding of the 
neurobiology of schizophrenia and possibly reveal novel therapeutic 
targets. 
The equivocal nature of excitatory signaling in relation to 
abnormal prefrontal cortical activity may stem from critical gaps in our 
understanding of glutamate. Although often described as the primary 
excitatory neurotransmitter in the brain (Coyle and Puttfarcken 1993; 
Marino et al. 2001), we are only now unmasking how the many 
components of this complex network of receptors, membrane-
expressed enzymes, transporters, and release mechanisms function in 
an integrated manner to regulate the neurotransmitter actions of this 
amino acid. Extant data indicate the existence of multiple glutamate 
release mechanisms by astrocytes (Araque et al. 2000; Bezzi et al. 
1998; Parpura et al. 1994; Pasti et al. 2001; Ye et al. 2003) that may 
independently maintain glutamate concentrations in distinct 
compartments (e.g., synaptic and extrasynaptic; Bridges et al. 2012). 
If this is the case, a hypo- and hyper-glutamatergic state may exist in 
these separate compartments. 
System xc− is an example of a poorly understood regulator of 
glutamate homeostasis that may exert profound control over multiple 
aspects of synaptic function (Baker et al. 2002; Moran et al. 2005; 
Moussawi et al. 2009; Moussawi et al. 2011). Originally identified over 
thirty years ago as a sodium-independent glutamate transporter 
(Bannai and Kitamura 1980), system xc− functions as a cystine-
glutamate antiporter or exchanger that couples the uptake of one 
molecule of extracellular cystine to the release of one molecule of 
intracellular glutamate (Bannai 1986; Piani and Fontana 1994). 
Nonvesicular glutamate release by system xc− regulates synaptic 
activity by stimulating extrasynaptic receptors including inhibitory 
group II metabotropic glutamate receptors (Baker et al. 2002; Kupchik 
et al. 2011; Moran et al. 2005; Pow 2001), which is thought to then 
inhibit synaptic neurotransmitter release (Battaglia et al. 1997; Moran 
et al. 2005). Thus, manipulations of system xc− activity could 
differentially impact levels of extracellular glutamate in extrasynaptic 
and synaptic compartments. An important question to be addressed is 
whether increased system xc− activity in the prefrontal cortex is 
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sufficient to manipulate behaviors thought to stem from excitatory 
signaling within the prefrontal cortex, especially since extant data 
suggest that system xc− activity in the prefrontal cortex may be altered 
in schizophrenia (Baker et al. 2008; Do et al. 2000; Raffa et al. 2011). 
The purpose of the current set of studies was to determine 
whether system xc− activity in the prefrontal cortex may influence 
sensorimotor gating, in part because it may be altered in schizophrenia 
as a result of abnormal excitatory signaling in the prefrontal cortex 
(Koch and Bubser 1994; Kumari et al. 2008; Majic et al. 2011; 
Swerdlow et al. 2001; Wilmsmeier et al. 2010). Sensorimotor gating 
refers to the ability of the central nervous system to regulate the 
capacity of sensory information to influence behavior (Braff and Geyer 
1990; Graham 1975; Swerdlow et al. 1986). It is often assessed in 
rodents using prepulse inhibition, which involves measuring the 
inhibition of a startle response when the onset of the startle-eliciting 
auditory stimuli is indicated to the subject by a preceding, relatively 
mild acoustic stimulus. Attempts to reveal the neural basis of 
sensorimotor gating deficits in schizophrenia often involve the use of 
non-competitive NMDA receptor antagonists, such as phencyclidine, to 
disrupt prepulse inhibition of an acoustic startle response (Braff et al. 
1978; Geyer et al. 2001; Swerdlow et al. 2006). 
Materials and Methods 
Animals and Surgeries 
Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 
300–400 grams were individually housed in a temperature controlled 
room with a 12-h light/dark cycle with food and water ad libitum. The 
housing conditions and care of the rats were in accordance with the 
Animal Welfare Act, and all procedures were approved by the 
Marquette University IACUC Committee. The total number of rats used 
in these experiments was 172; each rat was tested only once. Rats 
used in the microdialysis studies were anesthetized using pentobarbital 
(50 mg/kg, IP) with atropine sulfate (1 mg/kg, IP) pretreatment to 
limit tracheobronchial secretions. One pair of bilateral guide cannula 
(20 gauge, 14 mm; Plastics One, Roanoke, VA) were implanted using 
coordinates (+3.1 mm anterior, ±1.0 mm mediolateral to Bregma, and 
−0.75 mm ventral from the surface of the skull at a 6° angle from 
vertical) derived from Paxinos and Watson (Paxinos and Watson 
1986). Following surgery, rats were provided acetaminophen (480 
mg/L) in their drinking water for 2 days and were given at least six 
days to recover prior to testing. 
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In situ hybridization 
Brains were rapidly removed and frozen in optimal cutting 
temperature solution (OCT, Sakura, Torrance, CA) in a dry ice and 
ethanol bath and then cut into 12 μm coronal sections. Standard in 
vitro transcription methods were used to generate riboprobes against 
xCT (Choi, Milwaukee, WI) which was subsequently diluted in 
hybridization cocktail (Amresco, Solon, OH) and tRNA. Sections were 
hybridized overnight at 55°C in a mixture of tRNA, formamide, 
dextran, NaCl, EDTA, Denhardt’s solution and 33P-labeled riboprobe. 
After hybridization, slides were rinsed in 2× SSC buffer (pH 7.0). They 
were treated with RNase A in a 0.5 M sodium chloride, 10 mM Tris, 1 
mM EDTA buffer for 30 min at 37 °C and then washed in the same 
buffer without RNase A for 30 min at 37 °C. Slides were stringently 
washed in 0.5× SSC for 30 min at 6 °C and then exposed to 
autoradiographic film (3 days) and then subsequently coated with 
Kodak autoradiographic emulsion NTB (Rochester, NY) and exposed for 
9 days to produce silver grains. Following standard autoradiography 
development, NTB emulsion-dipped sections were counterstained with 
0.5% cresyl violet. Photodocumentation of silver grains was achieved 
using dark field microscopy (Axioskop-2, Zeiss, Thornwood, NY) and 
Axiovision image analysis software (Zeiss, Thornwood, NY). 
[14C]Cystine Uptake 
Rats were decapitated and the brains were rapidly extracted and 
cut into 1 mm coronal slices using a brain matrix. Tissue punches 
(1.25 mm diameter, Stoelting, Wood Dale, IL) were collected from the 
medial prefrontal cortex and incubated at 37°C for approximately 30 
minutes on a nylon bolting cloth platform, submerged beneath 2 mm 
of standard buffer (Lobner and Lipton 1993); the standard buffer 
contained 124 mM NaCl, 3.0 mM KCl, 1.4 mM KH2PO4, 1.3 mM MgSO4, 
26 mM NaHCO3, 2.4 mM CaCl2, and 4 mM glucose, equilibrated with 
95% O2, 5% CO2; pH was 7.4. After a 30 min wash, the tissue was 
incubated for 10 minutes in standard buffer containing phencyclidine 
(0 or 3 μM) or the system xc− inhibitor (S)-4-carboxyphenylglycine 
(CPG; 0 or 1 mM). 14C-cystine (0.03 μ Ci/ml; PerkinElmer, Boston, MA) 
and DL-threo-β-Benzyloxyaspartic acid (10 μM; to prevent the uptake 
of cystine via XAG) was then added to the incubation buffer for ten 
minutes. Next, the tissue punches were washed 4 times in ice cold 
standard buffer and dissolved in 250 μl of 1% sodium dodecyl sulfate 
(SDS). One aliquot (100 μl) was used to measure 14C-cystine uptake 
by scintillation counting; a second aliquot (100 μl) was used to assess 
protein content by the BCA method. Cystine uptake (CPM/μg protein) 
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was normalized to the vehicle group run concurrently (i.e., in the same 
plate). 
In Vivo Drug Treatments 
Phencyclidine (0–3 mg/kg; NIDA Drug Supply Program, 
Research Triangle, NC) was dissolved in isotonic saline. N-
acetylcysteine (0–100 μM, Sigma Chemical Co., St Louis, MO) and CPG 
(0.5 μM; Tocris-Cooksin, Ellisville, MO) was dissolved in microdialysis 
buffer. 
Prepulse Inhibition 
Rats were placed on a platform in a sound attenuating chamber 
(27.62×35.56×49.53cm); Hamilton Kinder, CA) that rested on a 
motion sensing plate. A matching session was conducted to determine 
the magnitude of the startle response for each rat. This session 
consisted of a five minute habituation period followed by 20 trials; 17 
trials involved the presentation of a single auditory stimulus (pulse 
stimulus; 50 dB above the 60 dB background noise, 40 ms duration) 
and three trials in which a prepulse stimulus (12 dB above 
background, 20 ms duration) was presented 100 ms before the pulse 
stimulus. Rats were then assigned into the various treatment groups 
based on the magnitude of their startle response. At least one day 
later, an experimental session was conducted to assess sensorimotor 
gating. On this day, rats received a 5 or 10 min habituation period 
followed by 58 discrete trials; eight background trials with only 
background noise, 26 trials with only the pulse stimulus (50 dB above 
background), and 24 trials with the pulse stimulus being preceded by 
one of three prepulse stimuli (2, 6, or 15 dB above background). The 
percent of prepulse inhibition was determined as 100-(average 
prepulse startle response/average startle stimulus alone)*100. 
In Vivo Microdialysis 
Microdialysis probes, constructed as previously described (Baker 
et al. 2002). The active membrane, approximately 1 mm in total 
length, began 1 mm beyond the most distal aspect of the guide 
cannula to minimize the influence of tissue damaged by the guide 
cannula to our measures. Dialysis buffer (5 mM glucose, 140 mM NaCl, 
1.4 mM CaCl2, 1.2 mM MgCl2, and 0.15% phosphate buffer saline, pH 
7.4) was pumped through the probes at a rate of 1 μl/min. Drugs were 
administered as described below for each experiment. Reverse dialysis 
was used for local infusions since it permits delivery of a low 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Psychopharmacology, Vol. 226, No. 3 (April 2013): pg. 531-540. DOI. This article is © Springer and permission has been 
granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Springer. 
7 
 
concentration of a drug (especially when considering an average 
recovery rate of 7% that is typical of our probes) across time as well 
as across the dorsal-ventral axis of the prefrontal cortex. 
Histology 
Rats included in the microdialysis studies were given an 
overdose of pentobarbital (60 mg/kg, IP), and the brains were fixed by 
intracardiac infusion of 0.9% saline followed by 2.5% formalin 
solution. Brains were removed and stored in 2.5% formalin for at least 
seven days prior to sectioning. The tissue was then blocked and 
coronal sections (100 μM) were cut and stained with cresyl violet to 
verify probe placements. Rats determined to have misplaced guide 
cannula were excluded from all behavioral analyses. 
Statistics 
Primary comparisons involving only two groups (i.e., Exps 1 and 
5) were analyzed using an independent-samples T-test. Primary 
comparisons involving more than two groups were analyzed using 
ANOVA with drug treatment (i.e., phencyclidine, N-acetylcysteine) as 
between-subjects factors and prepulse intensity as a repeated 
measure. The presence or absences of CPG was used as an additional 
between subjects variable used in experiment 4. Significant 
interactions and main effects were further analyzed using Tukey HSD 
(p<0.05). 
Design of experiment 1 
This experiment was designed to characterize system xc− in the 
prefrontal cortex. First, we used in situ hybridization to determine the 
distribution of mRNA of xCT, the active subunit for system xc−. Next, 
we measured 14C-cystine uptake in ex vivo tissue punches obtained 
from the prefrontal cortex in the absence or presence of the system 
xc− inhibitor CPG to confirm the existence of cystine-glutamate 
exchange by system xc−. 
Design of experiment 2 
The purpose of this experiment was to select a dose of 
phencyclidine for subsequent experiments. Rats received an acute 
injection of phencyclidine (0–3 mg/kg, SC) ten minutes before being 
placed in the startle chamber. Testing was conducted as described 
above. 
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Design of experiment 3 
This experiment was designed to determine the impact of 
increased cystine-glutamate exchange on phencyclidine-induced 
deficits in prepulse inhibition. To do this, we reverse dialyzed the 
cysteine prodrug N-acetylcysteine (0–100 μM) directly into the 
prefrontal cortex for one hour prior to and after phencyclidine (0 or 1.5 
mg/kg, SC) administration. One hour after phencyclidine, the probes 
were removed and rats underwent prepulse inhibition testing as 
described above. 
Design of experiment 4 
This experiment was designed to verify that N-acetylcysteine 
antagonizes phencyclidine-induced deficits in prepulse inhibition by 
increasing system xc− activity in the prefrontal cortex. To do this, the 
system xc− inhibitor CPG (0 or 0.5 μM), was infused into the prefrontal 
cortex. Twenty minutes later, N-acetylcysteine (0 or 30 μM) was added 
to the dialysis buffer such that CPG and N-acetylcysteine were co-
infused until prepulse inhibition testing. One hour after CPG and N-
acetylcysteine treatment began, phencyclidine was administered (0–
1.5 mg/kg, SC). One hour post phencyclidine, the probes were 
removed and rats underwent prepulse inhibition testing as described 
above. 
Design of experiment 5 
This experiment was used to determine whether phencyclidine 
directly influences the rate of cystine-glutamate exchange by system 
xc−. To do this, we measured the uptake of 14C-cystine uptake in 
prefrontal cortical tissue punches incubated in the absence (N = 9) or 
presence (N = 7) of phencyclidine (3 μM). The concentration of 
phencyclidine chosen exceeds estimates of NMDA receptor affinity for 
this compound by 3–15 fold (Morris et al. 2005). 
Results 
System xc− appears to be differentially expressed across 
subregions of the prefrontal cortex. The distribution of xCT mRNA 
within the prefrontal cortex reveals a particularly prominent lateral 
band of xCT mRNA contained primarily in the prelimbic cortex (see 
Figure 1). The uptake of 14C-cystine by tissue punches obtained from 
this subregion of the prefrontal cortex was significantly reduced by the 
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system xc− inhibitor CPG (t(14)=12.4, p<0.001) revealing the existence 
of functional cystine-glutamate exchange by system xc− in this region. 
 
Fig. 1 Cystine-glutamate exchange by system xc− activity is present in the 
prefrontal cortex. (a) A representative coronal section displaying the expression 
pattern of xCT mRNA via in situ hybridization (left, dark field photomicrograph). The 
right illustration, adapted from (Paxinos and Watson 1998), indicates that xCT mRNA 
is primarily expressed in prelimbic region of the prefrontal cortex (PrL) with minimal 
expression in the infralimbic cortex (IL). (b) The uptake of 14C-cystine by prefrontal 
cortical tissue punches in the absence or presence of the system xc− inhibitor (S)-4-
carboxyphenylglycine (CPG). The number of subjects for each group is listed in the bar 
graph. * indicates a difference from controls (t-test, p < 0.05). 
Phencyclidine produced a dose-dependent impairment in 
prepulse inhibition of the acoustic startle reflex (see Figure 2). An 
ANOVA with drug treatment as a between subjects variable and 
prepulse intensity as a repeated measure yielded a significant 
interaction (F(12,102)=5.77, p<0.001). Analysis of the simple main 
effects revealed a significant main effect of drug treatment at prepulse 
intensities of six (F(6,57)=9.20, p<0.001) and 15 dB (F(6,57)=14.79, 
p<0.001), but not two dB (F(6,57)=0.40, p=0.88). Post hoc analyses 
indicated that phencyclidine produced deficits in prepulse inhibition at 
doses exceeding 1 mg/kg (Tukey, p<0.05). A main effect of 
phencyclidine treatment (F(6,57)=5.80, p<0.001) on startle magnitude 
was obtained. Post-hoc analysis revealed that phencyclidine dose-
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dependently (1.25, 2.0 mg/kg) altered startle magnitude (Table 1; 
Tukey, p<0.05). 
 
Fig. 2 Phencyclidine produces a dose-dependent disruption of prepulse inhibition. 
The data is expressed as the mean (+ SEM) percent inhibition of the startle response 
to a loud auditory stimulus when preceded by a mile-modest, nonstartle-eliciting 
auditory cue ranging between 2–15 dB. Behavior depicted was obtained from rats that 
had received an acute injection of phencyclidine (PCP, 0–3 mg/kg; SC) ten minutes 
prior to testing. * indicates a difference from controls receiving 0 mg/kg phencyclidine 
(Tukey HSD, P<0.05). 
 
 
Figure 3a depicts the impact of N-acetylcysteine infused into the 
medial prefrontal cortex via reverse dialysis on phencyclidine-induced 
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deficits in sensorimotor gating. An ANOVA with drug treatment as a 
between subjects variable and prepulse intensity as a repeated 
measure yielded a significant interaction (F(8,54)=2.26, p<0.05). 
Analysis of the simple main effects revealed a significant effect of drug 
at every prepulse intensity (2 dB: F(4,31)=4.12, p = 0.01; 6 dB: 
F(4,31)=10.70, p<0.001; 15 dB: F(4,31)=7.15, p<0.001). Post hoc 
analyses indicated that phencyclidine-induced impairment of 
sensorimotor gating was attenuated by N-acetylcysteine at every 
prepulse intensity (figure 4; Tukey, p<0.05). There were no significant 
differences in the startle amplitude between the groups included in this 
study (ANOVA: F(4,33)= 0.21, p>0.05, table 1). The subregion of the 
prefrontal cortex targeted in the microdialysis studies is depicted in 
Figure 3b. 
 
Fig. 3 N-acetylcysteine infused into the prefrontal cortex antagonizes phencyclidine-
induced deficits in prepulse inhibition. (a) The mean (+ SEM) prepulse inhibition 
displayed by rats receiving N-acetylcysteine (NAC, 0 – 100 μM) into the prefrontal 
cortex followed 1 hour later by an acute injection of phencyclidine (0 or 1.5 mg/kg, 
SC). * indicates a significant difference from control rats receiving only saline (NAC 
0/PCP 0; Tukey HSD, p < 0.05). + indicates a significant difference from rats receiving 
only phencyclidine (NAC 0/PCP 1.25; Tukey HSD, p < 0.05). (b) The microdialysis 
probes were placed primarily in the prelimbic cortex (PrL), although aspects of the 
infralimbic (IL) may have been perfused as well. A representative coronal section 
illustrates the placement of a microdialysis probe. The tract created extends 
approximately 2 mm from the guide cannula with sampling only occurring from the 
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most ventral 1 mm because this is the portion of the probe containing the dialysis 
membrane. 
 
 
Fig. 4 N-acetylcysteine targets system xc− to antagonize deficits in prepulse 
inhibition produced by phencyclidine. The data is expressed as mean (+ SEM) prepulse 
inhibition displayed by rats receiving intra-prefrontal N-acetylcysteine (30 μM) (a) in 
the absence or (b) or presence of the system xc− inhibitor CPG (0.5 μM) co-infused 
into the prefrontal cortex. CPG was infused alone for 20 min, N-acetylcysteine was 
then added to the microdialysis buffer for 60 min prior to the injection of phencyclidine 
(1.5 mg/kg, SC). (a and b) * indicates a significant difference from respective vehicle 
controls (i.e., rats receiving NAC 0/PCP 0; Tukey HSD, p < 0.05). + indicates a 
significant difference from respective phencyclidine controls (NAC 0/PCP 1.5; Tukey 
HSD, p < 0.05). 
Figure 4 demonstrates that N-acetylcysteine antagonizes 
phencyclidine-induced deficits in prepulse inhibition by increasing 
cystine-glutamate exchange from system xc−. An ANOVA with drug 
treatments (ie, N-acetylcysteine and PCP treatment) as between 
subjects variables and prepulse intensity as a repeated measure 
produced a significant interaction between CPG treatment and drug 
treatment (F(1,46)= 4.57, p<0.05). To further deconstruct the 
interaction, we examined the simple main effect of drug treatment at 
each level of the CPG variable. In the absence of CPG, an ANOVA with 
drug treatment as a between subjects variable and prepulse intensity 
as a repeated measure yielded a significant interaction between these 
variables (F(4,42)= 3.01, p<0.05). Analysis of the simple main effects 
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revealed a significant main effect of drug treatment at every prepulse 
intensity (2 dB: F(2,23)= 12.41, p<0.001); 6 dB F(2,23)= 13.82, 
p<0.001; 15 dB F(2,23)= 12.35, p<0.001). Post hoc analyses indicated 
that N-acetylcysteine antagonized phencyclidine-induced deficits in 
prepulse inhibition when tested in the absence of CPG (figure 4a; 
Tukey, p<0.05). In the presence of CPG, a two-way ANOVA including 
treatment (N-acetylcysteine and phencyclidine treatments) as the 
between subjects variable and prepulse intensity as the repeated 
measures yielded a significant main effect of treatment (F(2,24)= 10.35, 
p<0.001) in the absence of a significant interaction between treatment 
and prepulse intensity (F(4,48)= 1.91, p>0.05). Post hoc analyses 
indicated that N-acetylcysteine failed to alter phencyclidine-induced 
deficits in prepulse inhibition when tested in the presence of CPG 
(Figure 4b; Tukey, p>0.05). There were no significant differences in 
the startle amplitude between the groups included in this study 
(F(2,23)= 1.10, p>0.05; F(2,26)= 0.49, p>0.05; table 1). 
A comparison of 14C-cystine uptake by tissue punches obtained 
from the prefrontal cortex did not reveal an effect of phencyclidine 
(t(25)=1.21, p>0.05). The mean values (± SEM) for vehicle and 
phencyclidine-treated tissue punches were 100±9.9 and 83±9.2, 
respectively. These data indicate that glutamate dysfunction produced 
by phencyclidine does not likely involve altered activity of system xc− 
in the prefrontal cortex. 
Discussion 
Abnormal glutamatergic signaling particularly in cortical 
structures has been linked to negative symptoms and cognitive deficits 
present in schizophrenia (Bunney and Bunney 2000; Deserno et al. 
2012; Goghari et al. 2010; van Veelen et al. 2010). As a result, 
identifying cellular mechanisms capable of regulating glutamate 
signaling may advance our understanding of the neurobiological basis 
of schizophrenia and facilitate the development of pharmacotherapies. 
System xc−, which exchanges extracellular cystine for intracellular 
glutamate (Bannai 1986; Bridges 2011), is a poorly understood 
regulator of glutamate homeostasis that may exert profound control 
over multiple aspects of synaptic function (Baker et al. 2002; Moran et 
al. 2005; Moussawi et al. 2009; Moussawi et al. 2011) and may be 
altered in schizophrenia (Baker et al. 2008; Bridges et al. 2012). The 
primary finding of the present report is that infusion of the cysteine 
prodrug N-acetylcysteine into the prefrontal cortex attenuates 
phencyclidine-induced deficits in sensorimotor gating and this effect is 
dependent upon intact system xc− activity. Collectively, these data 
illustrate the capacity of system xc− to regulate a complex behavior 
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involving the prefrontal cortex. Below, we discuss the potential 
relevance of this data set to our understanding and potential treatment 
of schizophrenia. 
In the current study, infusion of N-acetylcysteine into the 
prefrontal cortex antagonized phencyclidine-induced deficits in 
prepulse inhibition. The effects of N-acetylcysteine on prepulse 
inhibition are likely due to increased activity of system xc− in the 
prefrontal cortex, particularly within the prelimbic region of this 
structure. To establish this, we first verified the existence of system 
xc− in the prefrontal cortex by demonstrating the presence of mRNA 
for xCT, the active subunit of system xc−, and functional cystine-
glutamate exchange in prefrontal cortical tissue. Next, we found that 
reverse dialysis of N-acetylcysteine directly into this region 
antagonized phencyclidine-induced deficits in prepulse inhibition, an 
effect not observed when the system xc− inhibitor CPG was co-infused. 
This finding is similar to our previous observations that N-
acetylcysteine required intact system xc− activity to alter multiple 
behaviors including phencyclidine-induced deficits in working memory 
(Baker et al. 2008; Kau et al. 2008). Interestingly, this could stem 
from either the release of glutamate or the increase in intracellular 
thiols expected from increased system xc− activity (Baker et al. 2002; 
Bridges et al. 2012; Shimosato et al. 1995), which is expressed on 
astrocytes (Pow 2001). It is important to note that studies 
demonstrate the possibility that glutathione, a thiol that is dependent 
upon the transport of cystine for de novo synthesis, is capable of 
functioning as a signaling molecule (Janaky et al. 1999; Ogita et al. 
1995), and has been shown to influence excitatory signaling (Baker et 
al. 2002; Moran et al. 2005). In either case, the data are consistent 
with the conclusion that astrocytes may be key in regulating the 
activity of the prefrontal cortex in a manner that alters complex 
behaviors. Interestingly, activation of astrocytes has recently been 
shown to synchronize the firing large numbers of neurons through a 
glutamate-dependent manner (Angulo et al. 2004; Poskanzer and 
Yuste 2011). Thus, an important area of future research is the degree 
to which system xc− may be involved in these phenomena, especially 
since the origin of the glutamate may be nonvesicular (Angulo et al. 
2004). 
The present data may also have implications for our 
understanding and treatment of schizophrenia. Phencyclidine-induced 
deficits in prepulse inhibition has been used to study the neural basis 
of sensorimotor gating deficits observed in schizophrenia as well and 
to screen putative therapeutics that may exert antipsychotic effects 
(Geyer et al. 2001; Swerdlow et al. 2008). However, the constructive 
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validity of the phencyclidine model is questionable given that there are 
likely to be critical distinctions between the basis of abnormal 
behaviors produced by acute administration of phencyclidine and a 
chronic illness such as schizophrenia. In addition, the predictive 
validity of this model may also be questioned given that a number of 
currently used antipsychotics fail to alter phencyclidine-induced deficits 
in numerous behaviors, including prepulse inhibition. To this latter 
point, however, the inability of most currently used antipsychotics to 
significantly improve prepulse inhibition deficits produced by 
phencyclidine may parallel the poor efficacy of these medications in 
treating numerous symptoms associated with schizophrenia, 
particularly those thought to involve, at least in part, the prefrontal 
cortex such as sensorimotor gating and cognitive deficits (Japha and 
Koch 1999; Kumari et al. 2008; Swerdlow et al. 2001). In support, 
clozapine, which appears unique from other antipsychotics in that it 
significantly reduces sensorimotor gating and cognitive deficits in 
schizophrenia (Oranje et al. 2002), also has been shown to attenuate 
phencyclidine-induced deficits in prepulse inhibition (Bakshi et al. 
1994; Geyer et al. 2001; Li et al. 2011), but see (Cilia et al. 2007; 
Schwabe et al. 2005). 
An important question is the possibility that altered system xc− 
function may be evident in schizophrenia, and, if so, whether any 
potential disruption might impact the therapeutic utility of this target. 
In the current study, we did not find evidence that the 
psychotomimetic phencyclidine disrupted system xc− activity, although, 
as discussed above, there likely are key distinctions between abnormal 
behaviors produced by schizophrenia and acute phencyclidine 
administration. Further, we cannot rule out the possibility that 
phencyclidine alters system xc− activity under certain conditions (e.g., 
in vivo) or in a tissue-specific manner (e.g. cell type or brain region). 
Regardless, in schizophrenia, glutathione levels in the dorsolateral 
prefrontal cortex are significantly reduced (Do et al. 2000), which may 
indicate reduced system xc−. The reason for this is that intracellular 
cystine availability is thought to be the rate-limiting step in the 
synthesis of this key antioxidant (Kranich et al. 1998; Sagara et al. 
1993). Perhaps as a result of the decrease in glutathione, the protein 
levels of xCT, the active subunit for system xc−, is significantly 
increased in the dorsolateral prefrontal cortex in post-mortem tissue 
obtained from individuals afflicted with schizophrenia relative to 
controls (Baker et al. 2008). In support, decreased glutathione levels 
has been shown to be sufficient to up-regulate system xc− (Seib et al. 
2011). At the very least, these studies indicate that stimulation of 
system xc− is a potential therapeutic target for schizophrenia, which 
has been verified in a clinical trial (Berk et al. 2008). 
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Because system xc− is at the interface between oxidative stress 
and excitatory signaling, it is unclear how N-acetylcysteine reduces 
behavioral and neurochemical measures in rodents that may be 
relevant for schizophrenia (Baker et al. 2008; Chen et al. 2010; das 
Neves Duarte et al. 2012) or the actual symptoms of the disease in 
man (Berk et al. 2008; Berk et al. 2011). Specifically, system xc− 
couples the uptake of extracellular cystine to the release of 
intracellular glutamate (Baker et al. 2002; Bannai 1984; Bridges 2011; 
Cho and Bannai 1990). Evidence implicating the glutamate component 
of cystine-glutamate exchange include observations that system xc− 
regulates multiple aspects of synaptic activity including extracellular 
glutamate levels, activation levels of glutamate receptors, and synaptic 
plasticity (Baker et al. 2002; Kupchik et al. 2011; Moran et al. 2005; 
Moussawi et al. 2009; Moussawi et al. 2011). In addition, astrocytes 
have been shown to synchronize the activity of large numbers of 
neurons through a glutamate-dependent mechanism (Angulo et al. 
2004; Poskanzer and Yuste 2011). The potential significance of the 
latter point is evident from estimates that human cortical astrocytes 
may contact millions of neurons (Oberheim et al. 2006). Thus, 
increased glutamate release from system xc− may reverse several 
cellular events linked to schizophrenia ranging from NMDA receptor 
hypofunction to desynchronized firing of pyramidal neurons in the 
cortex. 
Evidence implicating the cystine-component of cystine-
glutamate exchange in the therapeutic effects of N-acetylcysteine 
stems largely from observations that 1) schizophrenia is associated 
with an imbalance in levels of antioxidants such as glutathione, the 
synthesis of which is at least partially dependent on system xc− as 
described above, and reactive oxygen species, or 2) depletion of 
glutathione in rodents recreates aspects of schizophrenia (Cabungcal 
et al. 2007; Gysin et al. 2011; Kulak et al. 2012; Steullet et al. 2006). 
In support, a decrease in glutathione inversely correlates with the 
severity of negative symptoms (Matsuzawa et al. 2008). Surprisingly, 
however, N-acetylcysteine has been shown to restore numerous 
interesting neurochemical abnormalities in glutathione-deficient mice 
without restoring glutathione levels (das Neves Duarte et al. 2012). 
Interestingly, the cystine and glutamate components of system 
xc− may converge on key cellular events thought to underlie aspects of 
schizophrenia, as demonstrated by the observation that depletion of 
glutathione is sufficient to produce NMDA receptor hypoactivity 
(Steullet et al. 2006). Collectively, these studies indicate that the 
study of system xc− may have profound impact on the integration of 
important components of neurophysiology such as excitatory signaling 
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and oxidative stress that are often studied in isolation as well as our 
ability to understand and treat debilitating CNS disease states such as 
schizophrenia. 
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